Drug Type Small molecule drug |
Synonyms [6R] 5,10-methylenetetrahydrofolate, [6R]-5,10-methylene-THF acid, Arfolitixorin + [6] |
Target |
Mechanism TYMS inhibitors(Thymidylate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US) |
Molecular FormulaC20H23N7O6 |
InChIKeyQYNUQALWYRSVHF-OLZOCXBDSA-N |
CAS Registry31690-11-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Phase 3 | US | 18 Dec 2018 | |
Colorectal Cancer | Phase 3 | JP | 18 Dec 2018 | |
Colorectal Cancer | Phase 3 | AU | 18 Dec 2018 | |
Colorectal Cancer | Phase 3 | AT | 18 Dec 2018 | |
Colorectal Cancer | Phase 3 | CA | 18 Dec 2018 | |
Colorectal Cancer | Phase 3 | FR | 18 Dec 2018 | |
Colorectal Cancer | Phase 3 | DE | 18 Dec 2018 | |
Colorectal Cancer | Phase 3 | GR | 18 Dec 2018 | |
Colorectal Cancer | Phase 3 | ES | 18 Dec 2018 | |
Colorectal Cancer | Phase 3 | SE | 18 Dec 2018 |
Phase 3 | Metastatic Colorectal Carcinoma First line | 59 | Arfolitixorin combination with 5-FU, oxaliplatin, and bevacizumab. (the Greek patient subpopulation) | hjfdqeklit(zvgfoscnyl) = dvodagstii pkqzvsujgv (fbosladxjc, 22.1 - 63.4) View more | - | 29 Jun 2024 | |
Leucovorin combination with 5-FU, oxaliplatin, and bevacizumab. (the Greek patient subpopulation) | hjfdqeklit(zvgfoscnyl) = nhnkcirebo pkqzvsujgv (fbosladxjc, 21.5 - 55.1) View more | ||||||
Phase 3 | 59 | Arfolitixorin+5-FU+Oxaliplatin+Bevacizumab | ddwcoygqur(plbrorbjyz) = vnontaqimd kdfjgymmpc (rafffcdezl, 22.1% - 63.4%) View more | Negative | 20 Jun 2024 | ||
Leucovorin+5-FU+Oxaliplatin+Bevacizumab | ddwcoygqur(plbrorbjyz) = wtebuxdfiu kdfjgymmpc (rafffcdezl, 21.5% - 55.1%) View more | ||||||
Phase 3 | Metastatic Colorectal Carcinoma First line | 490 | Arfolitixorin + 5-FU + oxaliplatin + bevacizumab | ovherocvsq(uuwwhztotn) = ejwgcbziec ploagnemqr (usysricykt ) View more | Negative | 04 Jan 2024 | |
Leucovorin + 5-FU + oxaliplatin + bevacizumab | ovherocvsq(uuwwhztotn) = minqyuhmhh ploagnemqr (usysricykt ) View more | ||||||
Phase 3 | 490 | (Group A) | upqgcaibvi(lyzaigakak) = yabhitxkga uithsqvyki (dngpyvwvtf, puebnfrbmu - offmgaigwl) View more | - | 26 Oct 2023 | ||
(Group B) | upqgcaibvi(lyzaigakak) = nnbdtcflck uithsqvyki (dngpyvwvtf, xkvpcwxcmh - xblambylwf) View more | ||||||
Phase 1/2 | Colorectal Cancer First line | 105 | bgpmsbxnxa(gpkuchybmz) = lyswuehrze kdlftbotgd (jlxpwuetrj ) View more | Positive | 29 Sep 2022 | ||
Phase 3 | Metastatic Colorectal Carcinoma First line | 490 | Fluorouracil+Oxaliplatin+Bevacizumab-BVZR+arfolitixorin | yfeiefukiq(qnmhsydfip): P-Value = 0.85 View more | Negative | 07 Sep 2022 | |
Fluorouracil+Oxaliplatin+Bevacizumab-BVZR+Folinic Acid | |||||||
Phase 1/2 | Colorectal Cancer BRAF mutation | 31 | Levofolinate Calcium+5,10-Methylenetetrahydrofolate | nsjodecdid(jiokdvgycc) = qwmmilihob enmnnvzmvl (lmcockgdcz ) | Positive | 30 Sep 2020 | |
Phase 1 | - | 33 | (200 mg/m2 of Modufolin®) | rftqdprphn(nqllusyaez) = vakyqeazdc iqlzygtnns (huaytdicck, vxuskvdsry - hojzthznwz) View more | - | 19 Mar 2020 | |
(350 mg/m2 of Modufolin®) | rftqdprphn(nqllusyaez) = iqyhticyiw iqlzygtnns (huaytdicck, odctrehnqz - pztaoyjlqa) View more | ||||||
Phase 1/2 | 18 | vqmjdbbqmf(ovccengzkh) = mslpakrzzs zyqjdjxlmf (bkkowsaszh, sbmlwuoxyq - coysfissgr) View more | - | 26 Jun 2019 | |||
vqmjdbbqmf(ovccengzkh) = zmpgzaimpr zyqjdjxlmf (bkkowsaszh, ymhsvhiasl - abuwcpiohu) View more | |||||||
Phase 1/2 | 67 | bomsqihtwx(iozkirpxcm) = 27 SAEs have been reported in 13 patients, 6 of these were judged as at least possibly related to arfolitixorin. No SAE were judged as solely related to arfolitixorin. yqnogbxtas (fdojjciybc ) | Positive | 21 Oct 2018 |